Braillon A, Lee S S, Valla D, Geoffroy P, Sauvanet J P, Lebrec D
Hepatic Physiopathology Research Unit, INSERM U 24, Hôpital Beaujon, Clichy, France.
Scand J Gastroenterol. 1988 Aug;23(6):691-5. doi: 10.3109/00365528809093934.
The acute effects of betaxolol (10 mg, intravenously), a new cardioselective beta-blocker, and propranolol (15 mg, intravenously) on splanchnic and systemic circulations were studied in two matched groups of six patients with portal hypertension due to cirrhosis. Similar decreases in hepatic venous pressure gradient and azygous blood flow--an estimation of superior portosystemic shunts--were observed after both drugs, whereas hepatic blood flow was not modified. The decreases in heart rate and cardiac index were also similar after betaxolol and propranolol. Both drugs induced a significant decrease in the fraction of cardiac output flowing through superior portosystemic shunts. These findings confirm that the marked effect of beta-adrenoceptor blocking agents on splanchnic circulation results both from the reduction in cardiac output and from a vasoconstriction of the portal vein territory, and demonstrate that this vasoconstriction of the portal vein area does not necessitate a beta 2-blocking activity of the drug. The similar efficiency of the two agents in decreasing the hyperkinetic circulation suggests that betaxolol merits further long-term study in the pharmacologic treatment of portal hypertension.
在两组各六名因肝硬化导致门静脉高压的匹配患者中,研究了新型心脏选择性β受体阻滞剂倍他洛尔(静脉注射10毫克)和普萘洛尔(静脉注射15毫克)对内脏循环和体循环的急性影响。两种药物给药后,肝静脉压力梯度和奇静脉血流量(一种估计肝上分流的指标)均出现类似程度的下降,而肝血流量未改变。倍他洛尔和普萘洛尔给药后,心率和心脏指数的下降情况也相似。两种药物均使流经肝上分流的心输出量比例显著降低。这些发现证实,β肾上腺素能受体阻滞剂对内脏循环的显著作用既源于心输出量的减少,也源于门静脉区域的血管收缩,并且表明这种门静脉区域的血管收缩并不一定需要药物具有β2受体阻滞活性。两种药物在降低高动力循环方面的相似效果表明,倍他洛尔在门静脉高压的药物治疗中值得进一步进行长期研究。